Projects per year
Fingerprint
Dive into the research topics where Arash Hatefi is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 5 Finished
-
Stem Cell-based Platform for Targeted Enzyme/Prodrug Therapy of Recurrent Ovarian Cancer
Hatefi, A. (PI) & Hatefi, A. A. (CoPI)
4/1/21 → 3/31/24
Project: Research project
-
A Nanotechnology Platform for Suicide Gene Therapy of Recurring Ovarian Cancer
Hatefi, A. (PI)
4/1/15 → 3/31/21
Project: Research project
-
Bioengineering a Safe and Efficient Vector Technology for Stem Cell Transfection
Hatefi, A. (PI)
National Institute of Biomedical Imaging and Bioengineering
5/15/14 → 10/31/17
Project: Research project
-
Development of a Nanotechnology Platform for Prostate Cancer Gene Therapy
Hatefi, A. (PI)
1/1/08 → 12/31/08
Project: Research project
-
Development of a Nature-Inspired Vector for Targeted Systemic Breast Cancer Gene Therapy
Hatefi, A. (PI)
1/1/06 → 12/31/06
Project: Research project
-
A high affinity and specificity anti-HER2 single-domain antibody (VHH) that targets trastuzumab’s epitope with versatile biochemical, biological, and medical applications
Nikkhoi, S. K., Heydarzadeh, H., Vandavasi, V. G., Yang, G., Louro, P., Polunas, M., Owji, H. & Hatefi, A., Feb 2024, In: Immunologic Research. 72, 1, p. 103-118 16 p.Research output: Contribution to journal › Article › peer-review
2 Scopus citations -
A quantitative MRI-based approach to estimate the permeation and retention of nanomedicines in tumors
Nomani, A., Yousefi, S., Sargsyan, D. & Hatefi, A., Apr 2024, In: Journal of Controlled Release. 368, p. 728-739 12 p.Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations -
Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice
Khoshtinat Nikkhoi, S., Yang, G., Owji, H., Grizotte-Lake, M., Cohen, R. I., Gil Gonzalez, L., Massumi, M. & Hatefi, A., Mar 15 2024, In: Journal for ImmunoTherapy of Cancer. 12, 3, e008295.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy
Nikkhoi, S. K., Li, G., Eleya, S., Yang, G., Vandavasi, V. G. & Hatefi, A., Jan 6 2023, In: Frontiers in immunology. 13, 1039969.Research output: Contribution to journal › Article › peer-review
Open Access21 Scopus citations -
Stem cell-assisted enzyme/prodrug therapy makes drug-resistant ovarian cancer cells vulnerable to natural killer cells through upregulation of NKG2D ligands
Li, G., Nikkhoi, S. K. & Hatefi, A., Apr 2023, In: Medical Oncology. 40, 4, 110.Research output: Contribution to journal › Article › peer-review
3 Scopus citations